tbuckley/cabot-search huggingface dataset:
CARDIAC GENE EXPRESSION PROFILE DISTINGUISHES AFRICAN-AMERICAN AND EUROPEAN-AMERICAN HEART FAILURE PATIENTS
Authors: Indrani Halder, Victoria Causer, Charles McTiernan, Bonnie Lemster, Ravi Ramani, Sumanth Prabhu, Mark Slaughter, Daniel Dries, George Tseng, Dennis McNamara
Journal: Journal of the American College of Cardiology (2016)
James Francis Hanratty
Authors: I. J. Higginson
Journal: BMJ (2014)

As surgeon lieutenant in the Royal Naval Volunteer Reserve, James Francis Hanratty served as the only doctor for six ships escorting convoys between Liverpool and the north Atlantic. He is mentioned in despatches for his calm leadership and medical competence when, on 18 July 1944, his ship was badly damaged in conflict. Among the crew were 46 injured, nine seriously, including executive officers. James, in addition to treating the wounded, took command and, aided by a tug, took the ship back to Portsmouth, where she was declared a total loss.

Before D Day, James, while duty officer on the ship in Falmouth, signed for a parcel. When he opened it, he was stunned to see plans for the D Day invasion, then a closely guarded secret. The parcel had been sent in error. He voluntarily confined himself to the ship, so that he could not inadvertently reveal the secrets.

In 1946 James went into general practice in the village …
AB0583 Does „minimal disease activity“ correlates with composite indices in patients with psoriatic arthritis?
Authors: J. Stolfa, L. Sedova, Z. Mares
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Minimal disease activity (MDA) [1] was proposed by EULAR as an alternative target of treatment of psoriatic arthritis (PsA) pats. in the absence of remission [2]. MDA comprises 7 items (TJC≤1; SJC≤1; pat. global assessment VAS score ≤ 2cm; pat.pain VAS score ≤1,5cm; HAQ≤0,5; tender enthesial points≤1; psoriasis BSA ≤3%). This target has also been incorporated in the recommendations of Czech Rheumatologic Association. At the same time we use Disease Activity Index for Psoriatic Arthritis (DAPsA) [3] for the assessment of the disease activity. <h3>Objectives</h3> We put the question of how MDA correlates with this index (DAPsA). <h3>Methods</h3> 103 consecutive patients with PsA treated according to standard algorythm were followed for two to four years (up to 5 controls) and their clinical activity was assessed using "disease activity index in PsA"(DAPsA) in four modifications [4]. We retrospectively assessed at each visit if the pats. reached MDA using 7 items (yes=1/no=0) and the number of items of MDA they fulfilled (0-7). In total 489 assessment was performed. Enthesitis (13 sites) was defined merely as a tenderness on palpation, which is a bit equivocal. Also a quantitative assessment of psoriasis (BSA) by rheumatologist is not too accurate. So we assessed the achievement of MDA using only 5 items (with omitting of enthesitis and BSA) in the same patients. <h3>Results</h3> (1) The Pearson correlation coefficient showed to be pretty high between the increasing number of items of MDA fulfilled and all 4 modifications of DAPsA (0,961-0,975), as well as the p-value p=(0,01)- tab.1. (2) When using 5-item MDA, the correlation coefficient remained high, and the p-value even increased (p=0,005). <h3>Conclusions</h3> MDA as a therapeutic target of pats.with psoriatic arthritis closely follows disease activity as assessed by composite measure DAPsA in all its modifications. Even omitting of enthesitidies and BSA (5-item MDA) maintains its ability to reflect disease activity. Both modifications of MDA are suitable as a therapeutic target for the treatment of patients with PsA. <h3>References</h3> <i>Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010 Jul;62(7):965-9.</i> <i>Gossec L, Smolen JS, Gaujoux-Viala C. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12</i> <i>Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis;69(8):1441-7.</i> <h3>Acknowledgements</h3> <i>Supported by the Research program of the Ministry of health of Czech Republic: IGA MZ CR: No. 000 000 23728</i> <h3>Disclosure of Interest</h3> None Declared
Abstract 531: RNA interference-mediated downregulation of uPARAP decreases invasion and migration property in glioma cells through reorganization of the actin cytoskeleton
Authors: Satoshi Takahashi, Masahiro Toda, Hikaru Sasaki, Takeshi Kawase
Journal: Cancer Research (2010)

Abstract OBJECTIVE: The aim of this study was to evaluate the role of membrane protein urokinase-type plasminogen activator receptor associated protein (uPARAP), which is one of the member of serine-protease cascade, urokinase plasminogen activator system, in the motile and invasive activities of glioma cells. METHODS: In the present study, we first evaluate expression of uPARAP in various normal tissues as well as glioma patients’ samples and glioma cell lines using quantative PCR and Western blotting. To evaluate the function of uPARAP, we silence the uPARAP gene using two independent siRNAs designed for uPARAP, and evaluate its function on motile and invasive activities of glioma cells by Boyden chamber migration and invasion assays. We also evaluate the function of uPARAP on rearrangement of actin cytoskeleton by staining glioma cells with Alexa Fluor 488 conjugated Phalloidin. RESULTS: uPARAP protein was expressed four out of four (100%) glioma samples regardless of its World Health Organization grade but did not express in normal brain control. Introduction of small interfering RNA targeted uPARAP into two different glioma cell lines; KNS42 and KNS81, resulted in down-reguration of uPARAP expression, and significantly suppressed glioma cells’ migration and invasion properties in vitro. Rearrangement of actin cytoskeleton was observed at Alexa Fluor 488 conjugated Phalloidin staining. In uPARAP knocked-down glioma cells, polymeric actin became organized in stress fibers and the lamellipodia disappeared. CONCLUSION: On the basis of our findings, we conclude that RNA interference-mediated down-regulation of uPARAP decreases invasion and migration property in glioma cells. The inhibition of invasion and migration property was mediated via reorganization of the actin cytoskeleton. Downregulation of uPARAP may be a novel anti-invasion therapeutic strategy for malignant gliomas. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 531.
Abstract 1225: Integration of HGF/Met signaling and hypoxia response in cancer cell invasion and proliferation
Authors: Young H. Lee, Donald P. Bottaro
Journal: Cancer Research (2012)

Abstract The cellular response to hypoxia is a major influence on the aggressiveness of primary tumors, yet much of how this response mechanism integrates with other signaling pathways is unknown. The MET proto-oncogene, which encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), is often overexpressed in cancers and can drive cell proliferation, invasion, and metastasis. Prior studies demonstrate that the Met tyrosine-kinase receptor drives cell invasion and metastasis under hypoxic conditions, and this invasive phenotype is lost if MET expression is inhibited. Hypoxia also has been shown to sensitize Met-activated pathways to drive HGF-induced invasion through an as yet undefined molecular mechanism. The high mortality rate of metastatic cancer makes it crucial to understand the functional integration of these two prevalent drivers of metastasis, hypoxia and Met signaling, and to identify ways to selectively block cancer cell invasiveness. We show that a chemically generated pseudo-hypoxic condition enhanced HGF-mediated cell migration and invasion in the papillary renal cell (PRC) carcinoma cell lines ACHN and UOK112. Enhanced HGF-driven invasiveness was associated with sensitization of the mitogen-activated protein kinase (MAPK) pathway and increased matrix metalloproteinase activity. HGF-stimulated cell proliferation, in contrast, was phosphoinositide 3-kinase (PI3K) pathway dependent and not enhanced under the same pseudo-hypoxic condition. Furthermore, MAPK activation in the presence of HGF and hypoxia negatively regulated HGF-induced Akt activation and mitochondrial reductase enzymes as detected by MTT assay. These data suggest that hypoxia promotes tumor invasion by sensitizing the MAPK pathway to HGF stimulation in PRC-derived cells while limiting and/or suppressing HGF activation of PI3K-mediated cell proliferation. Identifying the specific effectors responsible for the integration these signals will improve our understanding of pro-metastatic invasiveness and potentially identify novels targets for its selective blockade. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1225. doi:1538-7445.AM2012-1225
Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil
Authors: Martin Levitt, David Warr, Louise Yelle, Harry L. Rayner, Wycliffe S. Lofters, Danielle J. Perrault, Kenneth S. Wilson, Jean Latreille, Martin Potvin, Ellen Warner, Kathleen I. Pritchard, Michael Palmer, Benny Zee, Joseph L. Pater
Journal: New England Journal of Medicine (1993)

Although ondansetron was found to be effective as an antiemetic in numerous clinical trials of highly emetogenic combination-chemotherapy regimens that included cisplatin, its role in milder emetogenic regimens has not been fully defined. To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil.
MAGNETIC RESONANCE CHOLANGIOGRAPHY–AN OVERUSED INVESTIGATION IN PATIENTS WITH SYMPTOMATIC GALLSTONES?: Table 1
Authors: M J Mullan, M Connolly, R Thompson, R Kennedy, S Gillespie, J A Kennedy
Journal: Gut (2013)

Introduction The incidence of choledocholithiasis with symptomatic gallstones has been estimated to be 10–15%. Pre-magnetic resonance cholangiography (MRC), the common bile duct (CBD) was selectively imaged with intra-operative cholangiogram in patients with–(i) deranged liver function (II) a history of jaundice or acute pancreatitis (iii) a dilated CBD[⇓][1]. View this table: Table 1 Aims/Background The aim of this study was to assess the appropriateness of MRC in patients being assessed for choledocholithiasis. Method The medical records of all patients undergoing pre-operative MRC for a 12 month period (Jan 2011–Dec 2011) were identified. Data analysis included: indication for imaging, age, gender, WBC, CRP and liver function tests. Results One hundred and twelve (112) MRC investigations relevant to the study were performed, 35 had positive findings (31%). Regarding patients with choledocholithiasis: Sixteen of 35 had a Bilirubin >30 µmol/L. Those with pancreatitis were all >55 years and 3 had severe pancreatitis. Patients with biliary colic all had liver transaminases >twice the upper limit of normal. Analysis of patients with acute cholecystitis found 70%(n=16) were >55 years and 14 had a bilirublin >30 µmol/L. Conclusion A selective policy towards imaging the CBD yielded choledocholithiasis in 31% of cases. Pre-operative imaging allows both efficient scheduling of operating lists and ensures a surgeon with the necessary skills to perform laparoscopic bile duct exploration is available in theatre. This is significant as surgical units move toward immediate cholecystectomy for symptomatic gallstones. [1]: #T1
THU0524 Antidepressant use among Persons with Recent-Onset Rheumatoid Arthritis: A Nationwide Register-Based Study in Finland
Authors: E. Lönnroos, J. Jyrkkä, H. Kautiainen, H. Koponen, L. J. Virta, T. Pohjolainen, K. Puolakka
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Depression is a sizeable problem in rheumatoid arthritis (RA) but data on the antidepressant use is sparse. <h3>Objectives</h3> To investigate antidepressant initiations and the prevalence of antidepressant use among persons with recent-onset RA. <h3>Methods</h3> Persons (age ≥50) with incident RA (n=10356) during the years 2000-2007 were identified and data on their antidepressant purchases and comorbid conditions were obtained from the National Registers of Social Insurance Institution of Finland. Participants were categorized as former (antidepressant purchase during the year preceding RA diagnosis), new (first purchase after RA diagnosis) or non-users (no purchases during the study period) of antidepressants. <h3>Results</h3> Ten percent of participants (n=1034) were former users of antidepressants, and 9.4% (n=975) initiated the use after RA diagnosis. Cumulative incidence of antidepressant initiations among men was 4.8% (95% CI: 4.1 to 5.6) at two years after RA diagnosis and 11.4% (95% CI: 10.0 to 12.9) at the end of follow-up (mean: 4.4 years). For women, corresponding incidences were 7.1% (95% CI: 6.5 to 7.8) and 16.2% (95% CI: 14.9 to 17.5). Rate of antidepressant initiations was higher in women [HR 1.39 (95% CI: 1.21 to 1.60)]. The number of comorbidities before RA was linearly associated with antidepressant initiations (p&lt;0.001). The prevalence of antidepressant use among study participants was 11.3% (95% CI: 10.6 to 12.0) in the last follow-up year. <h3>Conclusions</h3> Antidepressant initiations were relatively frequent after RA diagnosis and significantly associated with comorbidity burden. This warrants the importance of psychological evaluation in early RA, especially among persons with several comorbidities. <h3>Disclosure of Interest</h3> None Declared
GENDER DIFFERENCE IN REGRESSION OF MYOCARDIAL HYPERTROPHY AFTER AORTIC VALVE REPLACEMENT
Authors: Kumiko Hirata, Makoto Orii, Yasutsugu Shiono, Takashi Yamano, Yoshiki Matsuo, Yasushi Ino, Tomoyuki Yamaguchi, Takashi Kubo, Atsushi Tanaka, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2015)
Abstract 2555: Aberrantly expressed AURKC increases tumorigenicity in cancer cells
Authors: Liang-Yi Hung
Journal: Cancer Research (2012)

Abstract Aurora-C (AURKC) belongs to the Aurora kinase family, which regulates many important events of the cell cycle. Aberrantly expressed Aurora kinases were demonstrated to be correlated with tumorigenesis. Recently, overexpression of AURKC was detected in human primary colorectal cancers, thyroid carcinoma, and several cancer cell lines. However, the regulation of and clinical index for overexpressed AURKC in somatic cancer cells are unclear. Herein, we showed that AURKC has an augmented expression in human cervical cancer with a statistical significance in its development. Overexpressed AURKC increases the proliferation, transformation, and migration activities in cultured cancer cells and in a xenograft model. Importantly, the kinase activity of AURKC is required for its ability of tumorigenesis. A reporter assay and Western blot analysis further demonstrated that PLZF, a transcriptional repressor, serves as a negative regulator for AURKC. The expressions of PLZF and AURKC mRNA in human cervical cancer displayed opposite patterns. Ectopically expressed HA-PLZF specifically repressed the expression of human AURKC, but not other Aurora kinase members, through recruitment to its promoter region. Taken together, our results provide important insights into human cervical cancer and AURKC expression, which may serve as a potential target for human cervical cancer therapy in the future. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2555. doi:1538-7445.AM2012-2555
Predictive factors for technically difficult endoscopic submucosal dissection in the colorectum
Authors: Keisuke Hori, Toshio Uraoka, Keita Harada, Reiji Higashi, Yoshiro Kawahara, Hiroyuki Okada, Hemchand Ramberan, Naohisa Yahagi, Kazuhide Yamamoto
Journal: Endoscopy (2014)

<b>Background and study aims:</b> Because of technical difficulty, colorectal endoscopic submucosal dissection (CR-ESD) is not widely performed. We aimed to determine risk factors for such technical difficulty as defined by long procedure duration (≥ 150 min), perforation, and piecemeal resection. <b>Patients and methods:</b> Patients with consecutive colorectal tumors treated with ESD between April 2006 and December 2010 were enrolled in a prospective cohort study. For prediction of technical difficulty, three types of factor were investigated: tumor location, tumor type, and colonoscopy-related. Cases were subsequently categorized into earlier and later periods (April 2006 – August 2008, 123 lesions; September 2008 – December 2010, 124 lesions). Variables were analyzed using multiple logistic regression, with subgroup analyses for each period. <b>Results:</b> 247 lesions were analyzed. Flexure location was an independent risk factor for technical difficulty as measured by longer procedure duration (odds ratio [OR] 4.1, 95 % confidence interval [95 %CI] 1.1 – 14.9), piecemeal resection (4.7, 1.1 – 17.2), or perforation (8.8, 1.1 – 56.8). Tumor with scarring or locally recurrent was a risk factor for longer procedure duration (4.7, 1.7 – 13.7), and for piecemeal resection (7.8, 2.4 – 25.0). Tumor of size ≥ 50 mm or spreading across ≥ 2 folds was the strongest independent risk factor for longer duration (6.3, 2.8 – 15.4), and was an independent risk factor for longer duration in both time periods (earlier, 3.3, 1.1 – 10.4; later, 27.4, 7.4 – 138.0). Flexure location was an independent risk factor for perforation (13.9, 1.5 – 129.1) and for piecemeal resection (5.1, 0.9 – 25.2) in the earlier but not the later period. <b>Conclusions:</b> Factors predicting technical difficulty of CR-ESDs were clarified. Their importance was influenced by the increasing experience of the endoscopist.
PROGNOSTIC VALUE OF PEAK OXYGEN CONSUMPTION IN CHRONIC HEART FAILURE PATIENTS FAILING TO ACHIEVE RESPIRATORY EXCHANGE RATIO &gt; 1,0
Authors: Ilya Giverts, Maria Poltavskaya, Oxana Dikur, Artem Doletsky, Denis Andreev, Ekaterina Yakubovskaya, Abram Syrkin
Journal: Journal of the American College of Cardiology (2015)
A potential role of EGFR-inhibitors for the prevention of BRCA1-related breast cancer.
Authors: LN Burga, N Tung, SL Troyan, BT Lee, M Houlihan, SE Pories, V Staradub, A Tobias, SE Come, K Coffey, GM Wulf
Journal: Cancer Research (2009)

Abstract Abstract #1110 Background: The majority of women who develop a BRCA1-related breast cancer develop an ER-/PR-/HER2- breast cancer. Endocrine prophylaxis does not prevent these ER- breast cancers. Therefore, there is a need to develop novel chemoprevention agents in this population. 67% of BRCA1-associated ER- breast cancers also overexpress epidermal growth factor receptor (EGFR). We therefore examined EGFR as a potential target for chemoprevention&amp;#x2028; Methods: We isolated primary mammary epithelial cells (HMECs) from women with a germline BRCA1 mutation who underwent prophylactic mastectomies and from age-matched controls without a mutation who underwent reduction mammoplasties. We used a three-dimensional matrigel-based colony formation assay to assess clonality and proliferative capacity of these cells as well as their response to EGFR-inhibition. Flow cytometry was used to determine the number of EGF binding sites per cell. As a corresponding mouse model we used conditional MMTV-Cre BRCA1-/-p53+/- mice. Results: HMECs from BRCA1 mutation carriers and from controls express EGFR to a similar extent as HCC1937 BRCA1-associated triple-negative breast cancer cells (5x103 binding sites/cell). In ex vivo 3D-cultures we observed that HMECs derived from BRCA1 mutation carriers showed greater clonal and proliferative capacity when compared to normal controls. However while the HMECs derived from BRCA1 mutation carriers and normal controls were equally sensitive to the growth-inhibitory effect of Erlotinib at concentrations as low as 0.2 μM, the ID50 for HCC1937 breast cancer cells was &amp;gt; 10 μM. Similar findings were observed in murine MECs derived from normal control mice as well as BRCA1-/-p53+/- mice which develop breast cancer at the age of 7 to 8 months. Both groups of murine MECs were equally sensitive to Erlotinib growth inhibition. Conclusion: MECs derived from breast tissue of women and mice with a germline BRCA1 mutation express EGFR and are highly sensitive to growth inhibition with the EGFR inhibitor Erlotinib. In contrast, BRCA1-associated HCC 1937 breast cancer cells are more resistant to Erlotinib inhibition despite EGFR expression. We are now studying whether Erlotinib given via oral gavage daily has the potential to delay or prevent breast cancer in this mouse model of BRCA1-related breast cancer. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1110.
The Usefulness of Tc-99m HMPAO Labeled WBC SPECT in Eosinophilic Gastroenteritis
Authors: KWANG JAE LEE, KI BAIK HAHM, YOUNG SOO KIM, JIN HONG KIM, SUNG WON CHO, HOON JIE, CHAN HEE PARK, HYUNEE YIM
Journal: Clinical Nuclear Medicine (1997)

Tc-99m HMPAO labeled WBC SPECT was performed in 5 patients with eosinophilic gastroenteritis before and after successful medical therapy. The imaging findings were graded according to the following imaging scheme: grade 0, no uptake; grade 1, uptake < bone marrow; grade 2, uptake < liver; grade 3, uptake > liver. In no patient was the diagnosis made radiologically or with colonoscopy. The sites of involvement were identified with Tc-99m HMPAO WBC imaging in all patients before treatment and the radionuclide imaging studies were all negative after therapy.
Rare Axillary Metastasis From Squamous Cell Carcinoma of the Tonsil
Authors: Cheng-Yi Cheng, Ting-Fu Su, Yau-Hsan Lin, Ching-Liang Ho, Wen-Sheng Huang
Journal: Clinical Nuclear Medicine (2013)

Tonsillar squamous cell carcinoma (SCC) is rarely involved in axillary lymph nodes. We describe herein a rare case of tonsillar SCC involved in axillary lymph nodes. A 55-year-old man with a history of a wide excision of the left tonsil and concurrent chemoradiotherpy for the tonsillar SCC 1year ago was presented to us with dysphagia. Except for the confirmed tumor over the retropharyngeal space, whole-body FDG PET/CT demonstrated a hypermetabolic lesion about 1 cm in size in the right axilla. Histopathology proved as a metastatic tonsillar SCC. The cancer staging and therapeutic regimens were thus altered.